Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RRx-001 + irinotecan + temozolomide
- Development stage
- Preclinical
- Lead developer
- EpicentRx
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**RRx-001 + irinotecan + temozolomide** is an investigational combination regimen involving three distinct agents: RRx-001, irinotecan, and temozolomide. - **RRx-001** is a cysteine-directed, hypoxia-activated small molecule with multiple mechanisms relevant to cancer therapy, including *NLRP3 inflammasome inhibition*, *macrophage polarization*, *CD47 antagonism*, *vascular normalization*, and *epigenetic modification*[1]. - **Irinotecan** is a well-established topoisomerase I inhibitor that prevents DNA unwinding, leading to apoptosis in cancer cells. - **Temozolomide** is an oral alkylating agent that methylates DNA, inducing cell death in tumor cells. This combination is designed to exploit the chemosensitizing effects of RRx-001, resensitizing tumors to chemotherapy agents like irinotecan and temozolomide, typically in cases of treatment-resistant cancers[1]. Clinical trials have explored RRx-001 in combination strategies, often aiming to overcome acquired resistance and improve efficacy.
- Brand names
- None found for the specific triple combination
- Other names
- None found for the specific triple combination
02
Targets
CD47 (Cluster of Differentiation 47)DNAHb (Hemoglobin)NF-κBNLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on RRx-001 + irinotecan + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RRx-001 + irinotecan + temozolomide.